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ABSTRACT  
Background: The Institutional-Review-Boards (IRB) frequently give unfavorable opinions 
to evaluated studies due to deficiencies in informed consent forms (ICFs), which delays 
the ethical  approval of the study and increases waste in research. Objective: To analyze the 
extent to which IRB in our center gives unfavorable opinions due to documents deficiencies 
and to evaluate types of objection. Material and methods: Retrospective observational study 
of decisions during the first review by the IRB in our center (2012-2015). We carried out a 
systematic review of minutes when decisions on approval of studies are collected. If not approval, 
we analyzed appealed objections. Results: 1858 clinical studies were evaluated by the IRB. 1558 
required informed consent for participating (83.9%, CI95%:82.1-85.5), 987 were not approved 
during the first review due to deficiencies in ICFs (63.3%, CI95%:60.9-65.7). The main causes 
of objections for non-approval were unreadability (11.7%, CI95%:10.6-12.9), inadequate 
information given about access to personal data rights (9.2%, CI95%:8.1-10.2), biological 
samples management (7.8%, IC95%:6.9-8.8), and expected benefits (7.6%, IC95%:6.7-8.6). 
Conclusions: Deficiencies in ICFs are an important reason for non-approval of protocols 
evaluated by an IRB. There are three fundamental weaknesses on which the IRB plays a key 
role: 1) improving readability; 2) adapting them to regulations concerning data protection and 
biological materials management; 3) avoiding misleading information towards enrollment.
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Introduction
The informed consent process is an essential part of clinical research, which main 
aims are to respect and promote participants autonomy and protect them from 
potential harm. For participants, signing of the informed consent forms (ICFs) is 
meant to indicate their agreement to participate in a study and confirm that they 
understand them. According to an international guidelines1-4, consent documents 
must contain detailed information regarding different legal and ethical aspects. 
Before being enrolled in a medical investigation, patients have to be aware of certain 
aspects such as the nature and purpose of the study, available alternatives, risks and 
benefits, or the voluntary nature of their decision to participate. 
However, in recent years, ICFs have become increasingly complex and difficult for 
patients to understand6-14. In many cases, sponsors and institutions use them as a legal 
document and an instrument to protect themselves against litigation14, which further 
increases their complexity. Thus, obtaining informed consent for participation in a 
clinical study requires a high level of literacy skills. In fact, published studies support 
the fact that the language used in ICF is not comprehensible for most potential 
participants15-17.
In this context, the Institutional Review Boards (IRBs), when reviewing a proposed 
clinical research for approval, play a key role in safeguarding the rights, safety, and 
well-being of all trial subjects, as well as ensuring that any written material given to 
potential participants is understandable. The IRBs members make a comprehensive 
review of ICFs to guarantee these documents are in accordance with international 
guidelines and ethical standards. They ensure that these documents are free of 
mistakes, including missing information, avoiding the biased information with some 
information about risks or adverse events before giving favourable ethical opinion of 
the research. Other relevant aspects, such as potential risks of participation, the use 
and collection of biological samples, research data maintenance, and confidentiality 
protection are also reviewed by the IRBs. They also verify that patient´s expectations 
are not inappropriately raised due to exaggerated or overemphasized benefits in the 
ICF.
It is known that most applications do not receive the IRB´s favourable opinion during 
the first review, and further clarifications and modifications are required before the 
final decision18.
In an agreement with other authors19, we observed a lack of published information 
concerning the objections and recommendations from experts on the informed 
consent issues. Taking this into account, we conducted the following study to test 
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the hypothesis that one of the main causes for the IRB´s non-approval is related to 
deficiencies found in the informed consent documents. 
Our main objective was to analyse the extent to which our centre’s IRB gives 
unfavourable opinions during the first review of applications due to the deficiencies 
detected in the informed consent forms. Secondary objectives were to evaluate the 
type of objections raised by the IRB regarding aspects such as readability (assessed 
by an IRB member who is not a healthcare professional and represents patients), 
ICF length (the IRB at our hospital agreed that the document of more than 15 
pages would be considered excessive), the purpose of the study, goals and designs of 
the study, treatments a patient will receive, expected benefits and foreseeable risks, 
potential adverse events, and available alternatives as standard treatments in clinical 
practice. Other aspects, such as voluntary nature of the decision to participate, right 
to withdraw, data confidentiality, or sponsor and investigator contact information for 
possible questions, were also evaluated. 
Material and methods
We conducted a four year retrospective observational study (from 2012 to 2015) of 
the decisions during the first review by the IRB in our centre. The IRB in our hospital 
(1350 beds) is one of the most important in our country in terms of number of 
applications for evaluation. The committee meetings take place twice a month, and 
after each of them, the minutes are recorded. We carried out a retrospective study 
of the minutes when the decisions on the approval of the study or non-approval are 
collected. In case of non-approval, we analysed the appealed objections. 
Primary outcome
The primary endpoint was the number of clinical studies evaluated by the IRB in 
our hospital that were not approved during the first revision due to the deficiencies 
detected in the informed consent documents.
Secondary outcomes
Following the current international guidelines1-5 that set out the principles and details 
of informed consent, we created a standardized form to extract secondary variables 
form eligible minutes. The data were tabulated and categorized according to the type 
of objection (table 1). 
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Table1. Secondary measured outcomes were objections related to information 
deficiencies found in the informed consent forms.
• Identification data of the study (title, sponsor and principal investigator)
• Goals and study design
• Readability
• Excessive length of the ICFs
• Expected therapeutic benefits (induction to get involved, misunderstandings or misinterpretations)  
• Personal data protection law reference (European Parliament 2001) 
• Foreseeable risks
• Data confidentiality (handling, and record keeping) (European Parliament 2001)
•  Information provided about the rights that the data owner has to access his personal information, 
rectify it, cancel it or oppose to his data being treated according to the Spanish  data protection 
law (ARCO rights) (Spanish Data Protection Agency 2014)
• Voluntary nature of the participation
• Potential adverse effects
• Alternative treatments
• Communication of results of tests performed and procedures
•  Information provided about biological materials that are going to be used for genetic testing (use, 
storage and property rights of the samples according to the Spanish regulation (Official Spanish 
Gazette 2007)
• Information provided to the mature- minor, a parent or legal guardian in studies in children
• Publication of the results
• Information about new evidence that may influence decision to participate
• Information provided to potential pregnant partner
• Name and contact information for questions
• Availability of liability insurance 
We also assessed whether the study received unfavourable opinions due to other 
reasons different from informed consent issues (objections associated with design or 
local aspects), and whether the application corresponded to a multicentre study or 
to a local research project. Medical specialties involved in the research studies were 
also evaluated.
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Eligibility criteria   
We evaluated the IRB resolutions of all clinical studies, including interventional 
(clinical trials) and non-interventional researches, assessed by the IRB whose decision 
on approval during the first review has been registered in the meetings’ minutes 
during four years (from 2012 to 2015).
La Paz University Hospital IRB, which oversees all clinical research at the institution, 
approved the study protocol.
Statistical Analysis
Data management
A database was designed to reflect the Case Report Form’s content, in which a data 
entry matrix with possible ranges or values was established, along with the various 
consistency rules between the variables. The quality of information received through 
exploratory analysis aimed at detecting discrepancies in the values, out-of-range 
values or missing values. Exploratory analysis also provided information on the 
distribution of the main variables to be studied and provided guidance on possible 
transformations.
General considerations
The information included was: the mean, standard deviation, median, maximum, 
minimum and 25% and 75% quartiles. For categorical data, the frequency 
distributions (absolute and relative) were presented. In addition, the 95% confidence 
intervals were calculated, where appropriate. The statistical analysis was carried out 
using SAS 9.1 (SAS Institute Inc., Cary, NC, USA).
Sample size considerations
According to the available data on the activity of the IRB in our hospital, two 
meetings are held every month, except in August. Given that there could have been 
meetings out of the scheduled dates, it was estimated that around 20 to 23 meetings 
a year would have been held. In the study period (2012-2015) the IRB would have 
hold a total of 80 to 92 meetings. Considering that the committee evaluates about 20 
initial study applications during each meeting, we would analyse 1600-1840 IRB´s 
initial resolutions. In a pilot study in which 10 minutes were assessed, we found a 
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15% of studies’ applications for evaluation did not require informed consent because 
of its design. According to this result, it was estimated that 1360-1564 ICFs would 
have been analysed by the IRB in the study period.  
Results
Table 2. Distribution of clinical studies evaluated by the IRB according to the 
medical specialty involved.
Medical specialty                        N of Clinical researches                              Percentage







Intrenal Medicine 79 4,2%








Psychiatry  36 1,9%
Intensive care unit 35 1,9%
Ophthalmology 32 1,7%
Genetic unit 26 1,4%
Urology 26 1,4%
Nutrition and dietetic 24 1,3%
Paediatrics 23 1,2%
Emergency  20 1,1%
General surgery 18 1%
Clinical pharmacy 18 1%
Traumatology 19 1%
Other   343 18,5%
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A total of 91 minutes corresponding to the IRB meetings over four years (2012-
2015) were analysed. In these meetings 1858 clinical studies were evaluated (1057 
clinical trials and 801 non-interventional studies). There was a similar number of 
studies evaluated a year (mean 464.5, SD±51.6). The main specialties that conducted 
clinical studies are shown in table 2. 
Out of the 1858 studies evaluated, 1558 (83.9%; CI95%: 82.1%-85.5%, which 
indicates the probability that the true value will fall between these two percentages) 
required a signed informed consent for subject’s participation. These analysed consent 
forms corresponded more to clinical trials (1038, 66.6%) than to non-interventional 
studies (520, 33.3%).
Global results
Total studies evaluated: 1858
Number of evaluated studies that required informed consent: 
1558/1858 (83.9%, CI95%:82.1%-85.5%)
Studies with objections to the informed consent documents:
987/1558(63.3%, CI95%:60.9-65.7)
The objections leading to the IRB´s non-approval of a proposed study were mainly 
related to inaccuracies in the ICFs (53.1%) and to a lesser extent to design inaccuracies 
(27.4%) and local issues (30.5%).      
Inaccuracies in the informed consent forms were primarily due to unreadability 
354/3012 (11.7%,CI95%:10.6-12.9), (251/354, 70.9% because of poor writing, 
and 103/354, 29.1% IRB members considered that the text was unintelligible to the 
potential participant), followed by inadequate information provided about the rights 
that the data owner has, for example to access his personal information, rectify it, cancel 
it, or oppose to the data being treated according to the Spanish data protection law 
(ARCO rights) 276/3012 (9.2%,CI95%:8.1-10.2), biological samples management 
according to our country regulations 236/3012 (7.8%,IC95%:6.9-8.8), expected 
benefits (induction to get involved, misunderstandings or misinterpretations) 
230/3012 (7.6%,CI95%:6.7-8.6), and excessive length 198/3012 (6.6%,CI95%:5.7-
7.5) (table 3).  
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Table 3. Type of objections raised by the IRB to informed consent documents. 
Type of objection N %
Unreadability 354 11,7%
ARCO rights* 276 9,2%
Information of biological materials management (genetic testing,  
use, storage and property rights) 236 7,8%
Expected benefits (induction to get involved, misunderstandings  
or misinterpretations)   230 7,6%
Excessive length 198 6,6%
Study identification data (title, sponsor or principal investigator) 150 5%
Purpose and design of the research 142 4,7%
Personal data protection law reference 126 4,2%
Alternative Treatments 122 4%
ICFs for the parents or guardians poor writing 116 3,8%
ICFs for mature minors poor writing 112 3,7%
Procedures and tests explanation (risks, whether they were  
routine or experimental, etc) 86 2,8%
Foreseeable risks 85 2,8%
Personal data confidentiality  85 2,8%
Name and contact information for questions 81 2.7%
Availability of liability insurance 81 2,7%
Information provided to potential partner pregnant 79 2,6%
 Information of new evidence that may influence decision  
to participate 66 2,2%
Potential adverse effects 66 2,2%
Request of a new ICF by major flaws that invalidate the submitted 58 1,9%
Publication of the results 42 1,4%
Voluntary nature of the participation 37 1,2%
Other   184 6.1%
*ARCO rights: rights that the data owner has to access his personal information, rectify it, 
cancel it or oppose to his data being treated according to the Spanish data protection law.
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Secondary endpoints were assessed according to whether they were omitted in the 
ICFs or were included but needed modifications prior approval (table 3). Regarding 
omissions, we observed that frequently omitted requirements were related to our 
country’s regulations on personal data protection and on investigation on biomedical 
materials, specifically about information provided to the patients of the ARCO rights 
(94%, 262 of the 276 objections related to ARCO rights were due to information 
omissions in the ICFs), and of the patient biological material management of samples 
taken because of their participation in the study (91,1%, 215 objections of the 236 
related to biological material management). When analysing these 215 objections 
due to omissions associated with samples management, we observed that 112 (52%) 
were because there were no mention about the patient´s rights to be informed of the 
results of analysis, in 51 (23.7%) there were no mention about the inability to use 
them for another purposes not related to the research, in 48 cases (22.5%) there were 
no mention about how it should be stored, and finally in 4 cases (1, 9%) there were 
no information at all about these samples management. The second most frequently 
omitted aspect was the availability of alternative treatments (111 objections out of 
122 related to alternatives to participating, 91%).
To a lesser extent the claims were due to aspects that were covered by the ICFs but 
required modifications. These text modifications were mainly related to poor writing 
of documents that were addressed to mature-minors (in the range of 12 to 17 in our 
country) in paediatric studies (77.7% of all objections rose to the ICFs for mature-
minors), patient information about data confidentiality (77.6%), and information 
about benefits (misunderstandings due to false expectations) (176 objections out of 
230 related to benefits, 76.5%). Table 4 shows modifications required by the IRB.
When we look at the top ten specialties involved in clinical researches, these 
accounted for 55.3% of applications for approval. Of all objections registered in the 
minutes evaluated, 36.4% (1098/3012) were related to applications of these top ten 
specialties. However, we observed that, only 18.1% of all objections registered to the 
ICFs were due to inaccuracies found in the consent forms of these top ten research 
specialities. Figure 1 shows objections during the first review concerning the top ten 
specialties involved in the researches. 
As table 5 shows, objections during the first review to the clinical studies of these top 
ten specialties were related more to the ICF than to the design or the local aspects.
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Table 4. Distribution of objections based on the changes required by the IRB 
for approval (additions to the informed consent forms or modifications of the 
information contained). 
                                                                                          IRB requested        Item omitted
Type of objection                                                  N        modifications     (addition to the
                                                                                           of the ICFs        ICF was required)
Unreadability 354 354 (100%) - 
ARCO rights* 276 14 (5.1%) 262 (94.%)
Information of biological materials  
management (genetic studies) 236 21 (8.9%) 215 (91%)
Expected benefits 230 176 (76.5%) 54 (23.5%)
Excessive length 198 198 (100%) -
Study identification data (title, sponsor or  
principal investigator) 150 58 (38,7%) 92 (61,3%)
Purpose and design of the research 142 142 (100%) -
Personal data protection regulation law 126 12 (9,5%) 114 (90,5%)
Alternative Treatments 122 11 (9%) 111 (91%)
ICFs for the parents or guardians poor writing 116 77(66,4%) 39(33,6%)
ICFs for mature minors poor writing 112 87 (77,7%) 25 (22,3%)
Procedures and tests explanation (risks, whether  
they are routine or experimental, etc) 86 41 (47,7%) 45 (52,3%)
Foreseeable risks 85 42 (49,4%) 43 (50,6%)
Personal data confidentiality 85 66 (77,6%) 19 (22,3%)
Name and contact information for questions 82 6 (7,4%) 76 (92,7%)
Availability of liability insurance 81 52 (64,2%) 29 (35,8%)
Information provided to potential pregnant partner 79 12 (15,2%) 67 (84,8%)
Potential adverse effects 66 41 (62,1%) 25 (37,9%)
Information of new evidence that may  
influence decision to participate 66 3 (4,5%) 63 (95,4%)
Request of a new ICF by major flaws that  
invalidate the submitted one 58 58 (100%) -
Publication of the results 42 6 (14,3%) 36 (85,7%)
Voluntary nature of the participation 37 19 (51,3%) 18 (48,6%)
Other 183 - -
*ARCO rights: rights that the data owner has to access his personal information, rectify it, 
cancel it or oppose to his data being treated according to the Spanish data protection law.
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Table 5. Reasons for non approval by the IRB at first review to clinical trials 
applications of the first ten specialties involved in researches.
TopTen specialties              Objections               Objections to the        Other objections
involved in reseraches       to the ICFs                   study design         (local requirements)
  1º– Oncology 113(51,4%) 29 (13,2%) 78(35,4%)
  2º– Haematology 91(53,2%) 31(18,1%) 49(28,6%)
  3º– Neurology 67(45,6%) 38(25,8%) 42(28,6%)
  4º– Cardiology 59(47,2%) 35(28%) 31(24,8%)
  5º– Rheumatology 56(51,8%) 25(23,1%) 27(25%)
  6º– Internal Medicine 40(50,6%) 18(22,8%) 21(26,6%)
  7º– Gastroenterology 35(43,7%) 16(20%) 29(36,2%)
  8º– HIV  36(52,9%) 12(17,6%) 20(29,4%)
  9º– Pharmacology 16(74,3%) 10(28,6%) 9(25,7%)
10º– Pneumology 31(47,7%) 15(23,1%) 19(29,2%)
Figure 1
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Objections to the study design
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Discussion
Written consent is needed for almost all clinical researches. In agreement with other 
authors9,18, we found that a high proportion of the studies evaluated by the IRB 
in our centre included informed consent documents for assessment (83.3% of all 
applications). When evaluating the process of obtaining informed consent and the 
written information for prospective participants, the IRBs must not only ensure that 
all these documents are written appropriately in a language understandable to the 
subject, but also make sure that the guidelines1-5 are followed and all information 
required is contained. 
Our results suggest that many non-approvals during the first review were due to 
deficiencies found in the ICFs. Thus, we observed that more than a half of them 
(53.1%) failed to meet the IRB´s standards and further response and modifications 
were needed before approval. Even though there are not many data about the success 
rates of applications to the IRBs concerning the evaluated ICFs, some authors 
previously identified deficiencies in applications associated with these documents. 
They observed, as we do in our work, that the ethical issue most frequently raised 
by the IRBs while reviewing protocols was related to the informed consent forms18.
In our study, we detected that the main reason of the IRB´s unfavourable opinions 
and non-approval on an initial assessment was unreadability. A 11.7% of the ICFs 
evaluated were not written appropriately, most frequently because of a poor quality 
translation into Spanish. Other authors previously9,23-29 have proved that ICFs given 
to the patients, in many cases are unreadable, providing them with incomplete or 
incorrect information of relevant aspects.
According to the most of those authors, although consent documents often included 
all the required information, participants do not understand what it was written. 
Published research shows that most of these forms are written for a grade reading 
level above 17 years30-33, which is higher than the reading level of the majority of the 
population in Europe or EEUU34,35. Falagas et al.36, in a review of ICFs from 1961 
to 2006 found that only 54% of patients properly understood the purpose of the 
study, only a 50% understood what it means to randomization, 47% voluntarism of 
participation, 50% the risks undertaken, and 57% the expected benefits.
In 2003 the Eastern Cooperative Oncology Group conducted a randomized 
study37comparing the use of an easy to read version of the ICFs versus standard consent 
statement. The authors observed lower consent anxiety and higher satisfaction in 
patients who were randomized to the intervention arm (easy to read ICFs) compared 
with the control arm (standard ICFs) but patient comprehension was not affected. 
Similarly, Davis et al.38 found that the degree of patient´s understanding of two 
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versions of the ICFs, one of university student´s level compared with other simplified 
corresponding to an educational level between 12-13 years were essentially the same 
(56% vs 58%) although patients preferred the simplified version. Taken this into 
account, other authors have investigated complementary strategies to help improve 
the understanding of the ICF. Flory et al.39 found that the interaction and feedback 
person- person is the most effective way to achieve a proper understanding of the 
information transmitted to the patient. Other strategies such as the use of media, or 
the involvement of a neutral educator spending more time with the patient proved 
to be useful as well39.
However, according to the GPC1-4 all of these ICFs have been previously reviewed and 
approved by the IRB. Our study found that unreadability is the main cause for the 
IRB non-approval, but modifications required by them for approval in terms of the 
readability were apparently insufficient. In this regard, Paasche-Orlow et al.40, analysed 
sample texts of informed forms provided by the IRBs of the U.S. medical schools. 
They observed that they generally fail to meet their own standards for readability 
regardless the level of research or the level of literacy. Readability standards ranged 
from 5th grade reading level (10-11 age range) to a 10th grade reading level (15-16 
age range). Their study suggests that 4th to 6th grade reading level (9-10 and 11-12 age 
range) would be a suitable target to be clear for candidates to participate. 
The second and third most frequent reason for objection was inadequate explanation 
in the ICFs of the rights, according to our country regulations, that patients have 
regarding who is allowed to access their personal data, rights of rectification or 
cancellation of their files, and the right to be opposed to having their personal data 
used for purposes that are not related to the study (ARCO rights) and biomedical 
materials management. In accordance with the Spanish law on the protection of 
personal data20 and biomedical research law22, informed consent forms have to 
mention the ARCO rights. In this regard, the lack of consensus and allowance for 
the different laws in different countries, which can explain this high prevalence of 
objections, often cause problems to the investigators in the informed consent process 
when conducting international researches41.
Apart from legislative issues, we also detected that the excessive length of the text 
was also a frequent reason for the IRB´s objections and non-approvals. Beardsley et 
al.42 observed that the page count for ICFs submitted for ethics approval increased 
dramatically in 6 years, from 3-9 pages in 2000 to 7- 21 in 2005. It should be also 
taken into account that longer text length means more complexity, and both aspects 
contribute to less understanding9. 
In our study we divided analysed aspects required in the ICFs into two categories 
according to the type of objections: items omitted and items that were included but 
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needed to be modified before approval by the IRB. Objections due to omissions were 
related mainly with our country regulations about ARCO rights21, and purpose and 
storage of tissue or biological samples22. In addition, we found a high proportion of 
objections concerning omitted information about available alternatives as standard 
treatment. In this regard, Resnik et al.43 found that only 17.4% of consent forms 
for oncology randomized controlled trials stated that patients could receive the 
treatments being investigated without participating in the study. In a more recent 
study41 researchers observed that 57.7% of ICFs of oncology clinical trials described 
alternatives but did not provide adequate information that could be useful to the 
decision making process.
Regarding modifications to the text required by the IRB, they were mainly associated 
with the language used in consent forms for mature-minors, confidentiality and 
explanations of benefits. Like other authors44-47, we observed that modifications 
requested about benefits gave unrealistically high expectations for therapeutic benefit 
from participation.
Our results draw attention that often the information given on the expected benefits 
needed to be modified because it created false expectations for potential participants. 
We also detected that alternative therapies were frequently omitted. This combination 
might mislead the patient towards the enrolment in a clinical study with persuasive 
rebasing methods. 
The proportion of objections to ICFs was lower in medical specialties that are usually 
involved in clinical research. In fact, more than 80% of the objections concerning 
ICFs corresponded to medical specialties different from the top ten that lead the 
clinical investigation in our hospital.
Study limitations
First, there were limitations derived from the study design itself as it is an observational, 
retrospective, and single centre study.  
On the other hand, even though the decisions recorded in minutes are the result 
of a consensus agreement among members of the IRB, the assessment of informed 
consent may be subjective in some respects. We must also take into account that the 
composition of the IRB has changed over the four years during which the data have 
been collected.
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Conclusions
Information documents that investigators delivered to patients for participation in 
a study have been previously reviewed and approved by the IRB. According to our 
work, the documentation’s deficiencies are the main reason for non-approval by the 
IRB while evaluating research protocols.
There are three fundamental weaknesses in these documents on which the intervention 
of the IRB is the key in its role of bridging patients and researchers. First, improving 
wording in order to be easier to understand by patients; second, adapting them to the 
state regulations mainly concerning personal data protection and biological materials 
management, and last but not least, avoiding misleading towards the enrolment since 
there is a tendency to exaggerate the benefits expected from taking part in the study 
and, at the same time, to omit available alternative treatments.
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Prevladavanje jaza između istraživača i 
pacijenata: uloga institucijskih odbora 
za procjenu u procesu informiranog 
pristanka
SAŽETAK
Pozadina: Institucijski odbor za procjenu (Etičko povjerenstvo) često daje nepovoljno mišljenje 
za istraživanja čiji se uzrok tumači nedostatkom obrazaca informiranog pristanka. Spomenuto 
odgađa etičko odobravanje istraživanja, povećavajući gubitak u istraživanju. Cilj: Analizirati 
u kojoj mjeri Odbor za procjenu u našem centru daje nepovoljna mišljenja zbog nedostataka 
dokumenata i procijeniti vrste prigovora. Materijal i metode: Retrospektivno opservacijsko 
proučavanje odluka pri prvom pregledu Odbora u našem centru (2012. – 2015.). Provodili 
smo sustavni pregled zapisnika o tome kada se prikupljaju odluke o odobravanju istraživanja. 
Ako ne odobrenje, analizirali smo žalbene primjedbe. Rezultati: Odbor je procijenio 1858 
kliničkih ispitivanja. Informirani pristanak za sudjelovanje zahtijevalo je 1558 (83,9 %, CI 95 
%: 82,1 – 85,5), 987 nije odobreno pri prvom pregledu zbog nedostataka u ICF-u (63,3 %, 
CI 95 %: 60,9 – 65,7). Glavni uzroci prigovora neodobrenja bili su nečitljivost (11,7 %, CI 
95 %: 10,6 – 12,9), neadekvatne informacije o pravima na pristup informacijama o osobnim 
podatcima (9,2 %, CI 95 %: 8,1 – 10,2), upravljanje biološkim uzorcima (7,8 %, IC 95 %: 
6,9 – 8,8) i očekivana korist (7,6 %, IC 95 %: 6,7 – 8,6). Zaključak: Nedostatci u obrascima 
informiranog pristanka važan su razlog zbog kojeg Odbor ne odobrava protokol. Postoje tri 
osnovne slabosti u kojima Odbor ima ključnu ulogu: 1) poboljšanje čitljivosti; 2) usklađivanje 
s propisima koji se odnose na zaštitu podataka i upravljanje biološkim materijalima; 3) 
izbjegavanje obmanjujućih informacija prilikom upisivanja.
Ključne riječi: obrasci informiranog pristanka, institucijski odbori za procjenu, prigovor, 
odobrenje.
